TrialJournal for immunotherapy of cancer2020

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).

Gil Awada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.